RONNEBERG AMY L 4
4 · Magenta Therapeutics, Inc. · Filed Jun 27, 2018
Insider Transaction Report
Form 4
RONNEBERG AMY L
Director
Transactions
- Conversion
Common Stock
2018-06-25+593,611→ 593,611 total(indirect: See Footnote) - Conversion
Series B Preferred Stock
2018-06-25−1,287,100→ 0 total(indirect: See Footnote)→ Common Stock (498,107 underlying) - Conversion
Series C Preferred Stock
2018-06-25−246,781→ 0 total(indirect: See Footnote)→ Common Stock (95,504 underlying)
Footnotes (2)
- [F1]The Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.
- [F2]The shares are held directly by Be The Match BioTherapies, LLC ("Be the Match"). Ms. Ronneberg is President of Be The Match and disclaims beneficial ownership of such securities, except to the extent of her pecuniary interest therein, if any.